IL1B and head and neck squamous cell carcinoma: Thus, MCC950 is able to decrease IL-1β, regulatory immune cells (MDSCs, Treg) and exhausted PD-1+ CD8+ and CD4+ T cells within HNSCC tumors in mice [59].